Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A, Guglielmi C, Bergantini S, Iacobelli S, van Biezen A, Milojkovic D, Gratwohl A, Schattenberg AV, Verdonck LF, Niederwieser DW, de Witte T, Kröger N, Olavarria E; Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Radujkovic A, et al. Among authors: milojkovic d. Biol Blood Marrow Transplant. 2015 Jul;21(7):1230-6. doi: 10.1016/j.bbmt.2015.03.012. Epub 2015 Mar 19. Biol Blood Marrow Transplant. 2015. PMID: 25797175 Free article.
Clonal gammopathies following alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation: association with chronic graft-versus-host disease and improved overall survival.
Lim ZY, Ingram W, Brand R, Akthari M, Milojkovic D, Ho AY, Devereux S, Pagliuca A, Duarte RF, Mufti GJ. Lim ZY, et al. Among authors: milojkovic d. Bone Marrow Transplant. 2007 Oct;40(8):747-52. doi: 10.1038/sj.bmt.1705805. Epub 2007 Aug 20. Bone Marrow Transplant. 2007. PMID: 17704796
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.
Khorashad JS, Milojkovic D, Mehta P, Anand M, Ghorashian S, Reid AG, De Melo V, Babb A, de Lavallade H, Olavarria E, Marin D, Goldman JM, Apperley JF, Kaeda JS. Khorashad JS, et al. Among authors: milojkovic d. Blood. 2008 Feb 15;111(4):2378-81. doi: 10.1182/blood-2007-06-096396. Epub 2007 Nov 2. Blood. 2008. PMID: 17982022 Free article. Clinical Trial.
Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis.
de Lavallade H, Punnialingam S, Milojkovic D, Bua M, Khorashad JS, Gabriel IH, Chaidos A, Olavarria E, Goldman JM, Apperley JF, Marin D. de Lavallade H, et al. Among authors: milojkovic d. Br J Haematol. 2008 May;141(5):745-7. doi: 10.1111/j.1365-2141.2008.07108.x. Epub 2008 Mar 7. Br J Haematol. 2008. PMID: 18331365 Free article. No abstract available.
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.
Khorashad JS, de Lavallade H, Apperley JF, Milojkovic D, Reid AG, Bua M, Szydlo R, Olavarria E, Kaeda J, Goldman JM, Marin D. Khorashad JS, et al. Among authors: milojkovic d. J Clin Oncol. 2008 Oct 10;26(29):4806-13. doi: 10.1200/JCO.2008.16.9953. Epub 2008 Jul 21. J Clin Oncol. 2008. PMID: 18645191 Free PMC article.
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.
Marin D, Milojkovic D, Olavarria E, Khorashad JS, de Lavallade H, Reid AG, Foroni L, Rezvani K, Bua M, Dazzi F, Pavlu J, Klammer M, Kaeda JS, Goldman JM, Apperley JF. Marin D, et al. Among authors: milojkovic d. Blood. 2008 Dec 1;112(12):4437-44. doi: 10.1182/blood-2008-06-162388. Epub 2008 Aug 20. Blood. 2008. PMID: 18716134 Free PMC article.
Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase.
Pavlů J, Kew AK, Taylor-Roberts B, Auner HW, Marin D, Olavarria E, Kanfer EJ, MacDonald DH, Milojkovic D, Rahemtulla A, Rezvani K, Goldman JM, Apperley JF, Szydlo RM. Pavlů J, et al. Among authors: milojkovic d. Blood. 2010 May 20;115(20):4018-20. doi: 10.1182/blood-2010-01-263624. Epub 2010 Mar 19. Blood. 2010. PMID: 20304808 Free PMC article.
Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma.
Gabriel IH, Sergeant R, Szydlo R, Apperley JF, DeLavallade H, Alsuliman A, Khoder A, Marin D, Kanfer E, Cooper N, Davis J, MacDonald D, Bua M, Foroni L, Giles C, Milojkovic D, Rahemtulla A, Rezvani K. Gabriel IH, et al. Among authors: milojkovic d. Blood. 2010 Sep 23;116(12):2033-9. doi: 10.1182/blood-2010-03-273706. Epub 2010 Jun 18. Blood. 2010. PMID: 20562327 Free PMC article.
Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantation.
Garland P, de Lavallade H, Sekine T, Hoschler K, Sriskandan S, Patel P, Brett S, Stringaris K, Loucaides E, Howe K, Marin D, Kanfer E, Cooper N, Macdonald D, Rahemtulla A, Atkins M, Danga A, Milojkovic D, Gabriel I, Khoder A, Alsuliman A, Apperley J, Rezvani K. Garland P, et al. Among authors: milojkovic d. Biol Blood Marrow Transplant. 2011 May;17(5):632-9. doi: 10.1016/j.bbmt.2010.08.002. Epub 2010 Aug 11. Biol Blood Marrow Transplant. 2011. PMID: 20708085 Free article.
136 results